CDT (Conduit Therapeutics) Earnings per share for the last twelve months
Conduit Pharmaceuticals is developing partnerships with pharma giants through licensing to create treatments for metabolic pathologies. The strategy is based on a narrow asset portfolio for treating lungs and kidneys, which eliminates laboratory costs. This chart of net profit per share over the last 12 months demonstrates revenue dynamics, where the -2820430.64 level reflects the current magnitude. The company's high potential is driven by R&D investments in selective kinase inhibitors.
CDT (Conduit Pharmaceuticals Inc): analytical breakdowns and indicator data
Conduit Pharmaceuticals (CDT) is growing its business through patent trading, although high operating expenses are temporarily limiting its profitability. This indicator assesses the efficiency of profit generation per unit of capital amid expensive borrowing costs. The trend in the rolling 12-month net income per share reflects management's ability to offset fixed costs. A declining curve signals increasing losses. For the investor, this is the primary marker of the business's fundamental stability.
